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1. Summary
Cell lineage-specific cellular proteins, oncogenes
from viral or cellular origin and tumor suppressor
genes encode tumor-specific/associated antigens.
Such antigens can elicit an major compatibility com-
plex (MHC) class l-restricted cytotoxic T lymphocyte
(CTL) response, either natura l ly in cancer patients or
following appropriate immunostimulation (in vitro
or in vivo). The reported immune responses in hu-
mans to the melanoma-associated MAGE gene pro-
ducts. GPIOO and tyrosinase. all self-proteins, sup-
port the idea to use wild-type p53 products as tar-
gets for T cells. An important step towards this goal
is identification of potential p53 CTL epitopes. We
identified the wild-type p53 peptides with the highest
affinity to the HLA-A*0201 molecule using two as-
says: the previously described MHC peptide-binding
assay and the peptide competition assay. We ob-
tained CTL against four p53 peptides with a high af-
finity for the HLA-A*0201 molecule. These findings
are discussed next to a short review concerning the
p53 literature.
2. Introduction
The therapeutic role of CTL and CTL epitopes
has recently been reviewed [1-4]. in mice viral onco-
genes of simian virus 40. polyoma virus, adenovirus
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and human papilloma virus (HPV) type 16 have been
shown to code for major histocompatibility complex
(MHC) class I-binding immunogenic peptides [3,5].
Immunization of mice with peptides derived from
the E7 oncoprotein of HPV-16 protected those mice
against outgrowth of HPV-16 transformed tumors
[6]. Eradication of tumors using adoptive transfer
with adenovirus-specific CTL is achieved in mice [7].
CTL epitopes of Epstein-Barr virus (EBV) antigens
restricted to different human MHC class I molecules
have been mapped during the last few years [4]. The
HLA-A*010L A*0201, A*0301. A*l 101 and A*2401
binding HPV-16 E6 and E7 derived peptides were
recently described [8.9]. Peptides derived from mu-
tated proteins, e.g., mutated p2l ras protein, and ab-
normal chromosome transiocation can also code for
tumor-specific CTL epitopes [1-3]. A mutant p53
peptide was shown to give rise to Kd-restricted CTL
responses recognizing the synthetic and processed
mutant p53 peptide [10]. The well-documented im-
mune responses in humans to the melanoma-asso-
ciated MAGE gene products [11-14], GPIOO [15]
and tyrosinase [16], all self-proteins, with the latter
two also expressed in normal melanocytes support
the idea to use wild-type p53 products as targets for
T cells.
The nuclear phosphoprotein p53 is composed of
393 amino acids [17], The normal p53 protein acts as
a suppressor of cell division. Although it is not com-
pletely clear how the p53 protein inhibits cell growth,
recent work provided some clues. The p53 protein
promotes the transcription of a 21 kDa protein by
binding to a specific DNA binding site [18]. This 21
kDa protein inhibits cyclin-dependent kinases
(CDK). which are needed to drive cells through the
cell cycle. The 21 kDa protein is called CIPI (CDK-
SSDI 0 1 6 5 - 2 4 7 8 ( 9 4 1 0 0 0 5 6 - W
interacting protein 1) [19] or WAF1 (wild-type p53-
activated fragment 1) [20]. Cell cycle arrest is needed
to prevent the replication of damaged DNA. p53 pro-
tein levels increase when cells are exposed to DNA-
damaging agents; in other words, there are physiolo-
gically relevant situations in which p53 is over-ex-
pressed [21,22]. p53 can send a cell into a pro-
grammed spiral of cell death, apoptosis, in response
to DNA damage [24-26]. This linkage between p53
and apoptosis is of direct importance for chemother-
apy and radiation treatments based on inducing
apoptosis [27] because drug-resistant tumor cells
might be the cells exhibiting loss of the p53 protein
[22,25], Mutant p53 confers resistance to radiation
and chemotherapy [22J. Otherwise the existence of
p53 null cells shows that p53 is not an absolute re-
quirement for cell division [28,29].
Inactivation of the p53 gene contributes to the
development of 50-60% of all human cancers
[30,31]. An inactivated p53 protein is correlated with
more aggressive tumors, metastasis and lower 5-year
survival rates in different forms of cancer [30-33].
Whether p53 alteration is an early or late event in
carcinogenesis may depend on tumor type. Inactiva-
tion of the p53 gene can be caused by different me-
chanisms. A mutation of one of the p53 alleles and
deletion of the other allele is the most frequent cause
of p53 inactivation [30,33]. The mutations are mostly
missense mutations [30.33]. Mutational hot-spots are
described depending on the particular type of cancer
[30.33,34]. Germline p53 mutations as in Li-Fraume-
ni patients provide a high risk for development of
cancer in many tissues including colon, ovarian and
breast carcinomas, soft tissue sarcomas, osteosarco-
mas, brain tumors and leukemias [35]. Some viruses
are capable of inactivating the p53 protein. The SV-
40 T antigen blocks the ability of the p53 protein to
bind to DNA by direct binding to the middle part of
the p53 protein [36]. The E6 oncoproteins of HPV-16
and -18 interact with the carboxyl-terminal region of
p53, promoting the degradation of p53 via the ubi-
quitin-dependent proteolysis pathway [37-40]. Re-
cently a gene has been described that encodes an E6-
associated protein (E6AP) which mediates the inter-
action between E6 and p53 and induces p53 degrada-
tion [41]. The E1B protein of the adenovirus type 5 is
also able to complex and inactivate wild-type p53
[42,43]. In soft tissue sarcomas the 90 kDa mdm-2
oncogene product is capable of binding to the p53
protein, thereby inhibiting p53 function [44,45]. An-
other mechanism of p53 inactivation is found in
breast cancer, where the p53 protein was found se-
questered in the cytoplasm instead of being trans-
ported into the nucleus [46], The mechanism of such
abnormal sequestration has not yet been determined.
The half-life of wild-type p53 is less than 30 min;
therefore the protein level in the cell is very low
[33,47]. Mutations of p53 are associated with a dra-
matically prolonged protein stability resulting in
much higher intracellular concentrations of the mu-
tant p53 protein [33,48], Viral oncoproteins influence
the half-life of p53 differently. The SV40 T antigen
and the Ad5 E1B protein stabilize the p53 protein in
the cell in contrast to protein level and half-life of p53
in E6 immortalized cells in which degradation of p53
is enhanced by the ubiquitin-dependent proteolytic
system [38].
Antibodies against human p53 are demonstrable
in an appreciable proportion of patients with breast
cancer [49-51], childhood cancers [52], lung cancer
[53] and prostate, bladder and thyroid cancer next to
lymphoma and leukemia [54]. The presence of p53
antibodies is associated with poor prognosis [51].
Over-expression of the p53 protein is important for
the formation of antibodies [53]. The antibodies pre-
sent in sera of cancer patients are directed against
wild-type p53 epitopes [54]. By a peptide mapping
procedure the wild-type epitopes recognized by p53
antibodies were identified [54]. The immunodomi-
nant regions are located at the carboxyl and amino
terminal ends of the protein [51,54]. The existence of
anti-p53 IgG antibodies indicates that a p53-specific
CD4 response occurs. Proliferative responses of
CD44 lymphocytes from cancer patients with over-
expressed p5.3 have indeed been observed and are
directed against wild-type p53 HLA class II-binding
peptides (Soussi, personal communication).
Our work is based on the hypothesis that p53-spe-
cific and therefore self-reactive T cells might evade
clonal deletion during thymic development because
the homologous p53 epitopes are not presented effec-
tively through endogenous processing. These p53 epi-
topes could become immunogenic in tumor cells dis-
playing an altered quantity and/or quality of p53
protein expression, and subsequently activate T-cell
responses. T cells directed against p53 might recog-
nize lower levels of p53 epitopes once the T cells
have been activated. In other words self-epitopes,
such as p53 epitopes, presented in a density not suffi-
cient for T-cell activation can be sufficient for target
cell recognition by already activated T cells. Stimula-
tion with p53 CTL epitopes in vitro could break tol-
erance and activate an autoreactive tumor-specific T-
cell response. We will present and discuss our latest
data concerning p53 peptide-specific CTL.
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3. Material and Methods
3.1. MHC peptide binding assay
The selection of p53 peptides was done by a com-
puter scoring program based on an HLA-A*0201
peptide motif [55] which has been previously de-
scribed [56]. The HLA-A*0201 motif was adjusted
by adding a threonine at position 2 and the C-term-
inal end as anchor residue [8]. Peptides were synthe-
sized by solid-phase strategies on an automated mul-
tiple peptide synthesizer (Abimed AM S 422) using
Fmoc chemistry. The purity of the peptides was de-
termined by reversed-phase HPLC and was found to
be routinely over 90% pure. Peptides were dissolved
in DMSO (final DMSO concentration 0.25%) and
diluted in 0.9% NaCI to a peptide concentration of
2 mg/ml and stored at -20°C. The T2 cell line, a gift
from Dr. P. Cresswell (Dcpt. of Immunology, Yale
University, New Haven, CT). was cultured in 1s-
cove's modified Dulbecco's medium (1MDM) (Bio-
chrom, Seromed Berlin) with 2 mM glutamine. 100
lU/ml penicillin, 100 /jg/ml kanamycin and 10% fe-
tal calf serum (PCS, Hyclone Laboratories. Logan,
UT). The T2 binding assay was performed as pre-
viously described [56], In short, washed T2 cells were
incubated overnight with peptide or 0.9% NaCI. Pep-
tides binding to the HLA-A*0201 molecule will sta-
bilize this molecule at the cell surface of the T2 cell
line and therefore increase the HLA-A*0201 cell sur-
face expression. Cells were stained by indirect immu-
nofluorescence with the mouse anti-HLA-A2 mono-
clonal antibody BB7.2 as a first antibody and goat
anti-mouse FITC-labeled F(ab')2 fragments as a sec-
ond antibody and measured on a FACScan flow
cytometer (Becton Dickinson, Franklin Lakes, NJ).
The fluorescence index (FT) was calculated by the
formula:
(mean fluorescence experimental sample - mean fluorescence background)
mean fluorescence background
Subsequent serial dilutions of peptide concentrations
were used to determine the concentration needed to
upregulate HLA-A*0201 to half maximum ('/j max)
fluorescence on the T2 cell line.
3.2. Peptide competition assay
The influenza matrix specific HLA-A*020I re-
stricted CTL clone Q66.9 was a generous gift from
Dr. H. Spits (NKI, Amsterdam, The Netherlands).
The CTL clone was grown on H LA-A*0201-positive
EBV-transformed B-cell line irradiated with 30 Gy in
RPMI (Gibco, Paislan, Scotland) with 2 mM gluta-
mine, 100 !U/ml penicillin, 100 ̂ g/ml kanamycin and
10% PCS (Hyclone Laboratories, Logan, UT). In the
competition cytotoxicity assay 2000 europium
( E u 3 + ) labeled T2 cells (40 ji\ complete [MOM med-
ium per well) were incubated with 10 /j.} of the influ-
enza CTL epitope (500 pg/ml, final concentration at
which plateau level of lysis by Q66.9 is just reached)
in the presence or absence of 10 ;<1 of one of the
competitor peptides in a 96-well U-bottomed plate.
The controls, background (no peptide) and maxi-
mum lysis (influenza CTL epitope only), were in-
cluded on every plate. The target cells were labeled
with Eu34 as described elsewhere [57]. After 30-min
incubation the influenza-specific CTL clone was
added in 40 /jl of complete IMDM medium at an
effector-to-target ratio of 5:1 for an additional 4 h of
incubation. After 4 h 20 ;jl of each culture superna-
tant was collected and mixed with 200 [i\ Enhancer
Solution (Wallac, Turku, Finland). Measurement of
the samples took place in a 1234 Delfia fluorometer
(Wallac). The percentage Eu34 release was calcu-
lated by the formula:
< Eu3 + release experimental well — background Eu3 * release)
x 100
(maximum Iïu3+ release — background Eu3^ release)
Serial dilutions of the concentration of competitor
peptide were used to determine the concentration
needed to block the lysis to '/2 max.
3.3. Induction of CTL responses
The in vitro CTL response induction method re-
cently published [58] was slightly modified. Pepiide
loaded and mitomycin-C-treated T2 cells were used
as antigen-presenting cells (APC) and co-cultivated
with HLA-A*0201-positive PBMC of a healthy do-
nor at a ratio of l T2 per 4 PBMC. Cells were cul-
tured for 10 days in 2 ml of standard medium
(RPM1-1640 Dutch modification (Gibco, Paislan)
containing L-glutamine, antibiotics, 15% pooled hu-
man serum and 40 ^g/ml peptide) in 24-well Costar
plates at a density of 2 million cells/well. Responder
cells were harvested on a Ficoll layer (Lymphoprep.
Nycomed-pharma. Oslo, Norway) and depleted for
CD4+ T cells using CD4-coated magnetic beads
(Dynal, Oslo, Norway) according to the manufac-
turer's instructions. Two million CD4-depleted re-
sponder cells were re-stimulated with a feeder mix
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consisting of 1 x 106 irradiated (3000 rad) autologous
PBMC and 2 x 10s irradiated (10 000 rad) autologous
B-LCL. Feeder cells were sensitized with 50 /*g/ml
peptide in serum-free IMDM for 2 h at 37'C washed
and added to the responders. The cells were cultured
in standard medium, however, without free peptide
and supplemented with 60 !U/ml human recombi-
nant interleukin-2 (rIL-2) (Eurocetus, Amsterdam.
The Netherlands). At day 17, responder cells were
harvested on Ficoll and cloned by limiting dilution:
10 or less responder cells were co-cultured with
l x 105 irradiated (3000 rad) PBMC and 5000 irra-
diated (10 000 rad), peptide sensitized, washed B-
LCL (from at least 2 different HLA-A*0201-positive
donors), in 100 fi\ of standard medium containing 60
ID rIL-2/ml and 1% leucoagglutinin (Sigma, St.
Louis, MO). Growing clones were expanded but sti-
mulated with peptide-sensitized washed B-LCL at a
2-week interval only. Cytotoxic specificity of re-
sponding cells against peptide-sensitized target cells
was tested in standard 4 h 51Cr-release assays. The
percentage 5lCr release was calculated by the formu-
la:
("Cr release experimental well - background "Cr release»
(maximum slCr release — background *'Cr release)
4. Results
4.1. T2 binding assay
Based on selection by a computer scoring program
(see Material and Methods) we synthesized 63 HLA-
A*0201 motif bearing p53 peptides with a cut-off of
more than 72 points or more (25 peptides with a
length of 9 amino acids, 22 decamers and 16 eleven-
mers). Among them 11 HLA-A*0201 binding p53
peptides (6 nonamer. 2 decamer and 3 elevenmerl
were found using the T2 binding assay (see Materials
and Methods) with a FI cut-off of 1.0 (final peptide
concentration 100 ^g/ml. Table 1 and 2A). In addi-
tion to the already published HLA-A*0201-binding
p53 peptides [58] we add 3 new HLA-A*0201-bind-
ing peptide. Serial dilutions of peptide concentrations
were used to determine peptide-binding affinity (Ta-
ble 2A). The concentration needed for up-regulation
of the HLA-A*0201 molecule to '/2 max was calcu-
lated from the results in Table 2A and is shown in
Table 3. second column. The ranking of the peplides
in Tables 2A and 3 is almost the same. Four rela-
tively strong binding peptides (p53(25-35), p53(187-
197), p53(65-73), and p53(65-74)) are identified next
to two moderately well-binding peptides (p53(!39-
147) and p53(264-272)) and five poorly binding pep-
tides (p53(24-32), p53( 193-203), p53(122-130),
p53(256-265) and p53(149-157)).
4.2. Peplide competition assay
Peptides selected by the MHC peptide-binding as-
say were tested in a peptide competition experiment.
First to demonstrate that the p53 peptides actually
bind to the groove of the HLA-A*0201 molecule in
a functional assay such as peptide competition for
CTL recognition. Second to compare the binding as-
say data and the competition assay data with respect
to the affinity of peptides for the HLA-A*0201 mole-
cule. The first issue was settled by the observation
that all eleven p53 peptides detected in the binding
assay as binding peptides could, at the highest pep-
tide concentrations, inhibit the lysis of CTL clone
Q66.9 which recognizes a HLA-A *0201-restricted
matrix influenza-derived peptide (Table 2B). Pep-
tides which did not bind to the HLA-A*020I mole-
cule were not able to block lysis by clone Q66.9 (data
not shown). Comparison of affinity for HLA-A*0201
in both tests, showed strong binding peptides are
strong/moderate competitors, that moderately bind-
ing peptides are relatively strong-to-poor competi-
tors, and that three out of four poorly binding pep-
tides are moderate/poor competitors (Tables 2B and
TABLE I
p53 PEPTIDES IDENTIFIED AS PEPTIDES BINDING TO
HLA-A*020I (cut-off level FI > 1.0 at a final peptide concentration
of lOOfjgm!)
The sequence numbers (seq. nr.) of the first and last amino acids
are shown. The peptides are ranked according to first seq. nr.
Peptides were selected using the sequence analysis and in vitro
assay for identifying peptides capable of binding to HLA-A*020I
[56]. ^The new H LA-A*020I -binding p53 peptides in addition to



















































































































A: TITRATION OF THE p53 PEPTIDES IN THE BINDING ASSAY (avg of 3 exp)
Binding of p53 peptides at concentrations of 100, 50, 25, 12.5, 6.25, 3.1, and 1.6 ^g/ml (final concentration in she test). Indicated is the
Fluorescence Index (FI). —, FI^0.20. The peptides are ranked in order of binding affinity to HLA-A*0201.

























































































B: TETRATION OF THE p53 PEPTIDES IN THE COMPETITION ASSAY (avg of 3 exp)
Competition of p53 peptides at concentrations of 100, 50, 25,12,5, 6.25, 3.1, t.oand 0.8 ^g/ml (final concentration in the test}. Indicated is the
percentage specific lysis. The peptides are ranked in order of competition ability.












































































































3). Peptide p53( 193-203) was a relatively poorly
binding peptide. In the competition assay, however,
this peptide was one of the best competitors (Tables
2B and 3). The explanation for this difference is at
present not clear. Different circumstances during the
two tests might influence the stability of the peptides
or the interaction of the peptides with the HLA-
A*0201 molecule.
4.3. Induction of CTL responses
We have previously reported the succesful genera-
tion of stable, peptide-specific CTL clones against the
p53(264-272) peptide [58]. With the same CTL re-
sponse induction protocol we obtained only weakly
specific responses against other wild-type p53 pep-
tides: p53(25-33), p53(65-73) and p53(187-197) [59],
After modification of the CTL response induction
protocol (CD4 depletion at day 10, and limiting dilu-
tion for cloning at day 17) we again tried to obtain
peptide-specific CTL clones against the three best
binding p53 peptides (p53(25-35), p53(187-197), and
p53(65-73), Table 2A). We succeeded in inducing
peptide specific clones against all three p53 peptides
(Table 4): one clone specific for peptide p53(25-35),
five against p53(187-197) and five specific for
p53(65-73). The newly obtained clones are as speci-
fic as the clones obtained with the former T-cel in-
duction protocol against peptide p53(264-272) (Ta-
ble 4).
5. Discussion
The HLA-A*0201 molecule is the most frequently
occurring class 1 allele of Caucasians (45%). Inactiva-
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TABLE 3
COMPARISON BETWEEN THE '/2 max OF BINDING AND
THE ' ;2 max OF COMPETITION FOR THE HLA-A*0203
BINDING p53 PEPTIDES
The peptides are ranked in order of \/i max of binding. The '/2 max
of binding is derived from Table 2A, The V; max of competition is
derived from Table 2B. A summary for binding and competition
ability is shown in the last column using an arbitrary score. +,
relative strong binding (^13 ^g/ml} or competitor (^8 ^g/ml)
peptide; ±, a relative moderate binding (14-26 ^g/ml) or
competitor (9-16 /ig/ml) peptide; — , a relative poor binding (27-
40 jig/ml) or competitor (17-24 /ig/ml) peptide.



















































tion of the p53 protein is reported in approximately
50-60% of all malignancies [3O-33]. HLA-A*0201
binding wild-type p53 peptides or HLA*0201-re-
stricted CTL recognizing wild-type p53 epitopes may
therefore have therapeutic potential for a large num-
ber of patients. We identified the p53 peptides with
the highest affinity to the HLA-A*0201 molecule
using two assays: the peptide binding assay and the
peptide competition assay. The results of both tests
were mostly complementary. One peptide p53(193-
203) showed a striking difference in the two tests. In
the peptide-binding assay it turned out to be a weakly
binding peptide but in the competition assay it was
one of the best competitors. It is unclear to us how
to interpret this finding. The immunological rele-
vance will be clarified by testing whether this peptide
or a length variant of it is processed and presented in
context of HLA-A*0201 and recognized by peptide-
specific CTL. We tried to induce CTL clones against
three p53 peptides with a high affinity for the HLA-
A*0201 molecule. Through modification of the CTL
induction protocol we succeeded in culturing peptide-
specific clones against all three p53 peptides in addi-
tion to previous reports [58,59], It remains to be de-
monstrated which if any of these HLA-A*0201-bind-
ing p53 peptides are processed selectively in tumor
cells versus normal cells.
In the near future we will compare cancer patients
and healthy controls for the frequencies of CTL-p
against HLA-A*0201-binding p53 peptides with a
limiting dilution analysis. Such an assay will help us
estimating the importance of p53 peptides as possible
T-cell targets in cancer cells [60]. Results of such an
assay will also inform us how to optimize vaccines, if
CTL-p will be measured before and after therapeutic
vaccinations in cancer patients.
Using p53-knock-out mice, one can obtain more
insight into tolerance for p53 peptides. We are test-
ing if Kb and Db binding mouse p53 peptides which
are non-immunogenic in normal mice can give rise to
p53 peptide-specific T-cell responses in p53-knock-
out mice in the absence of immunologie tolerance
for p53.
It is probably possible to overcome tolerance espe-
TABLE 4
LYTIC ACTIVITY OF CTL CLONES AGAINST P53 PEPTIDES
The code for the clones: e.g., 25-19 = fj53 peptide (25-35) clone ]9. An HLA-A*0201 positive EBV was used as Ihe target cell line in the "Cr
release assay. Spec: % specific lysis in 51Cr release assay (target cell loaded with the specific peptide). Aspec: % aspecific lysis in s'Cr release






































































































































"These two previously described clones [58] are shown for comparison with the present data.
176
daily if the self-proteins are not expressed at suffi-
cient levels at the time and place of tolerance induc-
tion. The results of serological analysis detecting p53
antibodies recognizing wild-type p53 means that B-
and T-cell responses against p53 do occur [54]. The
detection of CTL responses specific for wild-type p53
cross-reactive on processed peptides expressed at the
surface of tumor cells will hopefully only be a ques-
tion of time.
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